Tagged with clinical

Pharma Juan Fransisco Millán Sobaranes of Cetifarma, the council created by the pharmaceutical industry in Mexico for ethics and transparency, discussed the agency’s major milestones and its main priorities for ensuring transparency, notably with regards to patient groups, healthcare practitioners, and clinical trials.   You were part of the initial team…

Pharma Matthieu Brand, who has been heading the French affiliate of World Courier, AmerisourceBergen for 2.5 years now, shares with great passion the bright future lying ahead of the company in France, their “a la carte” logistics service offering in the fields of clinical trials and R&D, as well the ambitions…

Pharma The country president of Novartis Czech Republic explains the strategy that led the affiliate to become the number one pharmaceutical company in the Czech market, highlighting the significance of her team in accomplishing 8.4 percent market share. Furthermore, she shares news of recent significant investments into clinical trials and a…

Pharma György Bodoky, Head of the Oncology Department at Unified Szent István and Szent László Hospital, shares his insights on the state of oncological care in Hungary, the current effects of budget constraints as well his work founding the Hungarian Society of Clinical Oncology. As an introduction to our readers could…

Pharma The recently appointed CEO of Servier Hungary, Dr. Jan Frederic Kesselhut highlights his initial perceptions of the Hungarian pharmaceutical market and depicts the significant role that the Servier Research Institute of Medicinal Chemistry (SRIMC) in Hungary plays in the group’s overall R&D activities. He also elaborates on the crucial importance…

Pharma While the Italian clinical research community works to an excellent standard of quality, and is relatively competitive in terms of costs, regulatory differences with the rest of Europe pose significant challenges. Mariapia Cirenei and Stefano Marini, president of AICRO and EUCROF respectively, discuss these current challenges, and how the new…

Pharma Riccardo Palmisano, CEO of MolMed, discusses the latest developments for their late-stage clinical development products, and comments on the recent approval of Strimvelis, a gene therapy developed by GSK and MolMed. Can you please give our readers a brief rundown of the history of MolMed since its foundation in 1996?…

Pharma Mario Marazziti, President of the Italian XII Social Affairs Commission, discusses new legislation relating to clinical risk, the effects of the 2014 Pact for Health, and the efficiency of Italian healthcare in general. You were recently highly instrumental in the passing of new legislation relating to clinical risk. Could you…

Pharma Eclectic demographics, rapid patient recruitment, and a burgeoning population with a gradient of disease profiles—these seem to be the fundamentals truly driving growth in South Africa’s clinical trial industry. However, without the presence of proper mechanisms to arbitrate between regulators and researchers, the sustained growth of this industry may very…

Pharma Fresenius Kabi’s general manager for the MENA region discusses evolving attitudes towards clinical nutrition for critically ill patients and Egypt’s positioning as a knowledge center and source of medical professionals at the regional level. Fresenius is the undisputed provider of critical care worldwide. What products do you offer in Egypt…

Pharma Pharmaceuticals Mauritius’s economic stability, genetic diversity, cost competitiveness, and location make it a perfect location for clinical research; a fact the state is now actively promoting. A further vision of the Mauritian government is to transform the island into a medical hub for clinical research. Besides political and economic stability, a number of…

Pharma Pier Mannuccio Mannucci, Scientific Director of the Policlinico Foundation, describes some of the challenges the scientific community currently faces in Italy and what actions need to be taken to overcome these. He goes on to discuss the main objectives of the foundation and how the recent restructuring will provide better…